New QIAGEN and Element Biosciences Partnership Improves Workflow, Data Analytic Offerings for Element’s Disruptive AVITI Sequencer
11-2-23 (by: Scott Gleason) QIAGEN and Element Biosciences, Inc. have announced a strategic partnership to provide comprehensive next-generation sequencing (NGS) workflows for Element’s innovative AVITI™ System, a disruptive, high throughput benchtop sequencing system that offers a reduced cost profile for research studies. There has been a recent trend by company’s such as Element, PacBio, Oxford Nanopore, Ultima Genomics, and Singular Genomics to improve their workflow and secondary/tertiary analysis software offering to better compete against Illumina.
The collaboration aims to deliver complete solutions from sample to insight for researchers worldwide, addressing the increasing demand for streamlined NGS workflows. Element’s AVITI System will now be able to benefit from QIAGEN’s Sample to Insight NGS workflows. These workflows incorporate validated QIAseq panels and integrated bioinformatic solutions, including CLC LightSpeed and QCI Interpret software. QIAGEN’s platform-agnostic QIAseq panels are designed to facilitate efficient and accurate NGS library preparation. These panels, including the QIAseq miRNA Library Kit, the QIAseq xHYB Actionable Exome Panel, and the QIAseq Targeted DNA Pro Panel, which have been successfully validated for use with the AVITI sequencer. A new module, LightSpeed, integrated into the QIAGEN CLC Genomics Workbench Premium, offers AVITI System users cost-effective secondary analysis of whole genome sequencing (WGS) with exceptional runtimes. Additionally, QCI Interpret, a fully customizable software solution, streamlines NGS variant interpretation and reporting for both oncology and hereditary applications, having already generated over 3 million reports.
Nitin Sood, Senior Vice President and Head of the Life Sciences Business Area at QIAGEN, expressed the commitment of both companies to advance the field of genomics by providing innovative technologies and applications to accelerate research. Researchers can expect unparalleled insights across various genomic applications through this partnership.